Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
Crucially, Lupin is the exclusive first-to-file applicant for this product and is eligible for 180-day generic drug exclusivity in the U.S. market
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
The product will be manufactured at Lupin's facility in Nagpur, India.
Nearly 1 million people are living with multiple sclerosis in the United States. Spasticity is a commonly reported symptom for MS, with an estimated prevalence of spasticity of 67%
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
